Latest news from Eureka Therapeutics on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/eureka-therapeutics-announces-successful-preclinical-results-of-invisimask-human-antibody-nasal-spray-against-sars-cov-2-infection/?sc=rsin /articles/eureka-therapeutics-announces-successful-preclinical-results-of-invisimask-human-antibody-nasal-spray-against-sars-cov-2-infection/?sc=rsin Mon, 14 Dec 2020 08:00:00 EST Newly published study reports InvisiMask(tm), a self-administered single-dose nasal spray, protects against SARS-CoV-2 infection for up to 10 hours in mice Eureka Therapeutics